ADDED
Management's Discussion and Analysis of Financial Condition and Results of Operations 46 Item 7A.
The actual imposition or threats of tariffs, customs duties and fees by the U.S.
government and other nations in response and other retaliatory actions, such as trade protection measures, import or export licensing requirements, new or different customs duties, trade embargoes and sanctions and other trade barriers, as well as the impact of the Company s efforts to mitigate the effects of such tariffs or similar measures.
(Cooper, we or the Company), is a leading global medical device company focused on helping people experience life's beautiful moments.
Headquartered in San Ramon, California, Cooper sells products in over 130 countries and positively impacts over fifty million lives each year.
In November 2019, the MiSight 1 day contact lens became the first and only product approved by the United States Food and Drug Administration (FDA) for slowing the progression of myopia in children aged 8-12 at the initiation of treatment.
CooperVision received approval for use of the MiSight 1 day lens in China from Chinese National Medical Products Administration (NMPA) in August 2021 and in Japan from the Japanese Ministry of Health, Labour and Welfare (MHLW) in August 2025.
With MiSight, we offer the only contact lens approved by the FDA 1 , Chinese NMPA, Japanese MHLW to slow the progression of, and correct, myopia in age-appropriate children.
CooperVision is focused on greater worldwide market penetration of recently introduced products, and we continue to expand our presence in existing and emerging markets.
CooperVision Competition CooperVision competes in the spherical, toric and multifocal lens categories of the contact lens worldwide market against Johnson Johnson Vision Care, Inc., Alcon Inc., Bausch + Lomb as well as other smaller companies with limited product offerings.
REMOVED
Management's Discussion and Analysis of Financial Condition and Results of Operations 45 Item 7A.
(Cooper, we or the Company), is a global medical device company with a mission to improve lives one person at a time.
We partner with health care providers worldwide to improve patient outcomes and deliver practice-building resources and training.
By listening closely to the healthcare providers and patients, we fulfill the needs of today while focusing on the opportunities of tomorrow through innovation and strategic investment.
In November 2019, the MiSight 1 day lens became the first and only product approved by the United States Food and Drug Administration (FDA) for slowing the progression of myopia in children aged 8-12 at the initiation of treatment, and in August 2021, CooperVision received Chinese National Medical Products Administration (NMPA) approval for use of the MiSight 1 day lens in China.
With MiSight, we offer the only FDA approved 1 and first Chinese NMPA approved product to slow the progression of, and correct, myopia in age-appropriate children.
CooperVision is focused on greater worldwide market penetration of recently introduced products, and we continue to expand our presence in existing and emerging markets, both organically and through acquisitions.
AND SUBSIDIARIES acquired select Cook Medical assets focused primarily on the obstetrics, doppler monitoring, and gynecology surgery markets, a fertility company that specializes in sperm separation devices, and obp Surgical, a U.S.-based medical device company with a suite of single-use cordless surgical retractors with integrated light source and evacuation channels.
It is the only FDA approved non-hormonal IUD contraceptive option and is exclusively sold in the United States.
CooperVision Competition CooperVision's largest competitors in the worldwide market and its primary competitors in the spherical, toric and multifocal lens categories of that market are Johnson Johnson Vision Care, Inc., Alcon Inc.